Although NK cells naturally express TRAIL [37], modifying NK cells with a novel, potent TRAIL variant specifically targeting the most abundant DR on the ovarian cancer cell surface could increase potency and specificity. Here, TNFSF10 is linked to ovarian carcinoma.